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Huntington’s disease is the most prevalent in-
herited human neurodegenerative disorder world-
wide, affecting between 2 to 8 per 100 000 inhabi-
tants of Western countries, with an average age 
of onset close to 40 (range 2–80) and a usually 
slow progression over 10 to 30 years. Tremendous
progress has been made in the understanding of 
the mechanisms implicated in this disease since the
original description by George Huntington in 1872,
marked by the identification of the locus in 1983
and the responsible gene in 1993. Clinical features
include impaired motor control, manifesting as
motor impersistence and inability to perform 
tasks that require motor sequences, along with
abnormal movements such as chorea, athetosis,
impaired ocular saccades and characteristic gait
disturbances. Psychiatric and cognitive symptoms
are also prominent, including depression and psy-
chosis, with a high incidence of suicide, personality
changes, aggressive or uncontrolled behaviour,
impaired problem-solving abilities and ultimately
more diffuse neuropsychological deficits leading
to dementia. Genetically, the disease demonstrates
fully penetrant autosomal dominant inheritance
through a CAG trinucleotide repeat expansion in
the protein-coding region of the huntingtin gene.
There is an inverse correlation between the num-
ber of repeats and the patient’s age at onset of 
the disease. Due to a phenomenon referred to 
as anticipation, the number of CAG trinucleotide
repeats tends to increase when the disease is in-
herited from the father (paternal transmission),
with disease onset at a younger age in the affected
children. Despite 10 years of intensive study, the
exact route between mutant protein and neuro-
degenerative illness remains elusive.Protein aggre-
gation, mitochondrial dysfunction, transcriptional
dysregulation,calcium homoeostasis and signalling
anormalities, and organellar transport defects are
leading candidate disease mechanisms. Hunting-
ton’s disease pathology is characterised by marked
atrophy of the caudate and putamen, with involve-
ment of cerebral cortex, thalamus, subthalamus,
nucleus accumbens, globus pallidus and substantia
nigra pars reticulata. Within the caudate and puta-
men, the medium spiny GABA-ergic projection
neurons are selectively vulnerable. Huntington’s
disease progresses slowly but irremediably to a
state where patients are bedridden and demented,
followed by death from secondary complications
such as pneumonia. Current disease treatment is
limited to pharmacologic management of symp-
toms, mostly antipsychotics, both for the abnormal
movements and some psychiatric symptoms, and
antidepressants. Future therapies targeting under-
lying disease mechanisms are currently under
evaluation, raising tremendous hope for the devel-
opment of curative treatments.They include meta-
bolic support, neurotrophic intervention, cell re-
placement, transcriptional regulation and reducing
the expression of the causative gene using small
interfering RNA.
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Introduction
In 1872 George Huntington described a “here-
ditary chorea … confined to certain and fortunate-
ly few families, … [with] three marked peculiari-
ties …: its hereditary nature, a tendency to insanity
and suicide, [and] its manifesting itself as a grave
disease only in adult life” [1]. Since then, tremen-
dous progress has been made in the understanding
of the transmission and pathogenesis of this dis-
ease, with localisation of the gene in 1983 [2],
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followed by the description of the pathogenic
mutation in 1993 [3]. Huntington’s disease is a fully
penetrant autosomal dominantly inherited pro-
gressive neurodegenerative disease, characterised
clinically by abnormal movements, impaired motor
and emotional control, and cognitive decline. New
mutations are extremely rare. Prevalence in the
general western population is reported to be 2 to 
8 per 100 000. The mean age of onset is between 
35 and 40, but patients have been described to pre-
sent with initial symptoms from 2 to 80 years of age.
Disease duration is usually between 10 to 30 years,
until death occurs due to secondary causes, such as
pneumonia.
This article will outline the major clinical aspects
of Huntington’s disease, recent insights into its




The core feature of Huntington’s disease is chorea
(from the Greek “to dance”), comprising rapid,
fluid and semi-purposeful involuntary movements
involving virtually any part of the body, mani- 
festing as facial grimacing, eyelid elevation, head
bobbing, and writhing and jerking of the limbs. In
early stages of disease these movements are well
incorporated into normal motor activity, typically
with conversion of an involuntary movement into
a seemingly voluntary one (parakinesia), but over
several years they become more and more visible
and start to interfere with daily activities. Often,
slower distal athetoid movements coexist. Motor
control is altered, with impersistence and inability
to perform tasks involving motor sequences, ulti- 
mately leading to severe impairment of voluntary
movement. Previously thought to be a late mani-
festation, eye movement abnormalities, mostly
difficulty in generating voluntary saccades,are now
known to be an early sign of the disease [4]. Other
eye movement abnormalities include increased
latency of response, non-suppressible eye blinks 
or head movements associated with saccades and
reduced saccade velocity.Consistent with the origin
of the term chorea, Huntington’s disease gait has 
a characteristic dance-like aspect, the patient ap-
pearing to be thrown off balance by involuntary
movements and moving in a zig-zag pattern.
Approximately 5 to 10% of the patients pre-
sent with juvenile Huntington’s disease (defined 
as onset before age 20, also called the Westphal
variant), in which rigidity, dystonia and action
tremor are often the primary manifestations,
sometimes accompanied by cerebellar signs and
seizures.
In a cross-sectional analysis of 45 Venezuelan
Huntington’s disease patients, chorea, dysdiado-
chokinesia and oculomotor abnormalities were all
present in early stages of the disease, worsening 
in concert thereafter, while rigidity and dystonia
increased in later stages [5]. Among subjects first
rated to be disease-free and who subsequently
developed Huntington’s disease after more than 
5 years, slowing of rapid alternating movements 
or abnormal saccadic generation at first evaluation
was a highly sensitive (84%) and specific (69%)
predictor of Huntington’s disease development.
As the disease progresses, bradykinesia, dys-
tonia and gait difficulties worsen, and patients
eventually become bedridden. Associated abnor-
mal movements may appear, including myoclonus,
tics, bruxism and ataxia. Hypertonicity bears both
pyramidal (spastic) and extrapyramidal (rigid)
components. Dysarthria is a prominent feature,
often associated with dysphagia, which leads to
weight loss and infection.
Psychiatric and cognitive symptoms
In the early stages of Huntington’s disease, subjects
frequently experience impaired problem-solving
abilities, difficulties with visuospatial skills and
attention disorders, which can lead to a decline in
performance at work. Personality changes often
occur in early stages and may be associated with
depression, which is the most frequent psychiatric
disorder, affecting up to 50% of patients. The inci-
dence of suicide is high in Huntington’s disease
patients as well as Huntington’s disease at-risk 
relatives [6.] Other psychiatric features include
mood instability, outbursts of rage, psychosis,
paranoia, anxiety, irritability, mania or obsessive
behaviour. Apathy is a frequent complaint. With
disease progression cognitive impairment worsens
and leads to dementia [7].
From gene to disease
Genotype-disease presentation relationships
The gene locus involved in Huntington’s disease
was one of the first human disease loci to be
chromosomally mapped (to chromosome 4 [2]).
The nature of the mutation, discovered in 1993,
is a variable trinucleotide (CAG) repeat expansion
in exon 1 of the gene now known as huntingtin
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(also HD, IT15). This type of mutation is common
across a class of neurodegenerative disorders,
collectively known as polyglutamine (polyQ) dis-
eases because the trinucleotide repeat encodes 
an expanded stretch of glutamines in their corre-
sponding proteins. In Huntington’s disease a nor-
mal benign huntingtin allele carries 34 or fewer
CAG repeats, whereas an allele with 35 repeats or
higher predisposes to disease and alleles carrying
40 or more repeats are fully penetrant. Above the
disease-causing threshold, age of Huntington’s
disease onset is inversely correlated with CAG
repeat length. The careful study of heterozygous
Huntington’s disease mutation carriers in 83 kin-
dreds of a Venezuelan Huntington’s disease cohort
confirmed the major effect of CAG repeat length
on disease onset (accounting for 72% of the vari-
ance in age of onset overall), but further clarified
that among the majority of Huntington’s disease
cases (with repeat lengths of 40–58) repeat length
accounts for only 44% of this variance [8]. In 
the entire set of Venezuela kindreds residual
variance in onset (not attributable to CAG repeat
length) was estimated to be approximately 37%
genetic and approximately 63% environmental
(shared and unshared) [8]. Htt alleles carrying 
60 or more repeats invariably result in juvenile-
onset Huntington’s disease (see “Clinical manifes-
tations”) and 60 is also the mean CAG repeat size
in this patient group.Juvenile-onset disease is more
frequently inherited paternally than maternally,
presumably due to a higher probability of repeat
expansion through spermatogenesis. Such inheri-
tance is thus manifest as anticipation, where the
child’s disease has an earlier onset than that of the
disease-gene-carrying parent.
The huntingtin protein and its mechanisms 
of toxicity 
The discovery of the Huntington’s disease gene was
an important breakthrough, and it was anticipated
that the elucidation of the huntingtin protein’s
primary structure would bring rapid insight into 
the molecular and cellular mechanisms underlying
the disease. Despite the creation of many useful
genetic Huntington’s disease models [9, 10], how-
ever, the path toward a clear understanding of this
process has remained slow and arduous. Elucidat-
ing mutant huntingtin’s neurotoxic effects may 
be difficult due to the protein’s particularly large
size (3144 amino acids, 350 kDa) and apparent
multifunctionality. Huntingtin has been reported 
to interact with membrane lipids [11] and a 
large number of proteins [12, 13]. In some cases 
the mutant protein shows a differential affinity 
in its molecular or organellar interaction compared
to its wild-type counterpart, and these differen-
ces have been implicated in the disease process.
In addition, mutant huntingtin-driven protein
aggregation may be an important disease mecha-
nism.
It has been suggested that polyglutamine dis-
ease-related neurodegeneration results primarily
from a gain of function in the mutant protein.The-
oretical and experimental evidence have generally
supported the hypothesis that disease-causing
polyglutamine proteins are abnormally prone to
adopt beta sheet conformations, to self-associate
and to form large assemblies that recruit other
proteins [14, 15]. These abnormal and potentially
toxic protein complexes have been described as
aggregates or inclusions, the latter term referring
to structures that can be observed by light micro-
scopy. The nature of the exact molecular species
which cause(s) neurotoxicity has been a topic of
intense study and debate. This subject has come 
to the forefront because it is hoped that future
therapeutic interventions can target the toxic
species specifically by preventing its formation,
promoting its elimination or converting it into a
non-toxic form.
Although Huntington’s disease is caused by a
single mutant protein, Huntington’s disease patho-
genesis appears to be complex. The multipartite
effects of mutant huntingtin are probably due to 
its widespread distribution in the cell. Mutant
huntingtin appears to sensitise neurons to excito-
toxicity through interaction with glutamate recep-
tor complexes at the plasma membrane [16], asso-
ciation with calcium-regulating inositol triphos-
phate receptors in the endoplasmic reticulum [17],
interfering with mitochondrial calcium dynamics
[18]. Systemic administration of succinate dehydro-
genase inhibitors, which act on both complex II of
the mitochondrial electron transport chain (ETC)
and the tricarboxylic acid cycle (TCA), mimic
Huntington’s disease pathology. ETC and TCA
cycle abnormalities, which are also seen in human
Huntington’s disease brains, are likely to impair
many energy-dependent cellular pathways and
contribute to oxidative stress.
Characteristic changes in gene expression have
been observed in both human Huntington’s disease
and Huntington’s disease model systems [19, 20].
This effect is attributed to transcriptional dysre-
gulation through aberrant interactions between
huntingtin and various transcriptional regulators,
which may occur through soluble protein binding
or the sequestration of these factors into poly-
glutamine inclusions.
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Inhibition of organellar transport also appears
to contribute to the pathogenesis of Huntington’s
disease. Whereas normal huntingtin positively
regulates the neuritic transport of organelles, such
as vesicles containing brain-derived neurotrophic
factor (BDNF), the presence of mutant huntingtin
inhibits this process [21]. It is also likely that intra-
cellular inclusions block organellar movement
through axons or dendrites.
Presymptomatic and symptomatic testing
Genetic testing is now widely available for Hun-
tington’s disease, as well as for several other tri- 
nucleotide repeat diseases. Such testing should 
only be done after the ethical and social impli-
cations of the result are considered carefully, first
acknowledging the fact that having one family
member test positive immediately reveals that
many others are at high risk (see Cina and Fell-
mann, in this issue). Ethical issues also include 
who has a right to be tested, who has a right to 
the information and what the tested individual 
will do with the result – positive or negative.
Appropriate genetic counselling and neurological
and psychiatric evaluations are required in order 
to help the individual deal with the possible result
of the test.
Pathological and imaging findings
Atrophy and gliosis of the caudate nucleus and 
the putamen are the pathological hallmarks of
Huntington’s disease [22], although abnormalities
exist in the cortex, thalamus, subthalamus, nucleus
accumbens, globus pallidus and substantia nigra
pars reticulata. In the caudate and the putamen,
there is massive loss of GABA-producing medium
spiny neurons projecting to the external globus
pallidus, with relative sparing of the large aspiny
striatal interneurons. These cells contain intra-
neuronal inclusions, with mutant huntingtin pro-
tein and α-synuclein [23]. Glucose uptake is re-
duced in the caudate and putamen of Huntington’s
disease patients and can be measured by 18F-2-
deoxy-D-glucose PET scan [24]. Morphometric
MRI imaging shows a progressive atrophy of the
caudate and putamen which becomes statistically
significant approximately 11 or 9 years prior to
disease onset, respectively [25]. Heterogeneous
cortical thinning is also observed by MRI in indi-
viduals with preclinical Huntington’s disease, and
its spatial distribution pattern correlates with
specific neuropsychologic measures (symbol digit,
stroop, verbal fluency) [26]. Whole brain atrophy
has also been detected in longitudinal measures 
of early-stage Huntington’s disease patients over
periods as short as 6 months [27].
Treatments
Symptomatic treatments
The mainstay treatment for severe chorea has his-
torically been typical anti-psychotics like haloperi-
dol, but atypical agents (e.g. clozapine, quetiapine)
are now preferred because of their fewer extra-
pyramidal side effects. The potent presynaptic 
anti-dopaminergic tetrabenazine is very effective
in reducing chorea, but parkinsonism and depres-
sion limit its usage. Depression responds well to
standard SSRI therapy. Atypical anti-psychotics
are useful for managing psychosis, paranoia and/or
aggressive behaviour.
Surgical, neuroprotective and other currently 
experimental strategies
The development of surgical interventions for
Huntington’s disease has focused on foetal tissue
transplant strategies [28], which have shown evi-
dence of improvement in cognitive and motor
symptoms [29]. However, confirmation of benefit
awaits the results of larger ongoing trials.
Coenzyme Q10, an antioxidant and cofactor
involved in the mitochondrial electron transfer
chain, showed modestly encouraging results with
functional decline slowing after 30 months in a
randomised controlled trial [30]. Minocycline, a
tetracycline antibiotic, has also been shown to have
anti-apoptotic, antioxidant and anti-excitotoxic
effects in Huntington’s disease model systems [31].
In a small open-label clinical trial it also showed a
beneficial effect in Huntington’s disease patients
[32]. The potential benefit of high doses of the
nutritional supplement creatine is currently being
studied, based on favourable outcome in animal
studies, yet negative results have been reported in
a 1-year randomised controlled trial with lower
doses [33].
Histone deacetylase inhibitors, which may re-
verse transcriptional abnormalities [34, 35], are
currently in clinical trials. Given evidence for
deficits of both BDNF gene transcription [36] and
the axonal transport of BDNF-containing vesicles
in model systems [21], and the known importance
of BDNF in the differentiation and survival of the
striatal medium-spiny neurons that degenerate in
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Huntington’s disease, this trophic factor is also 
an interesting therapeutic candidate.
As mentioned above, the structural under-
standing and targeting of mutant protein aggre-
gates has a strong rational basis [15], but these
studies are still in an early phase. Complementary
approaches to limit the accumulation of toxic pro-
tein species have also been proposed.These are the
stimulation of autophagy [37] and the inhibition of
proteases such as calpains and caspases that may
generate huntingtin fragments with an increased
potential to aggregate [38, 39].
Recent breakthroughs in several scientific disci-
plines have resulted in a new approach to inhibit
the expression of mutant huntingtin at the level 
of its RNA transcript.The administration of newly
introduced nucleotide sequence-specific small in-
terfering RNAs to genetic Huntington’s disease
models has yielded impressive functional improve-
ments [40]. Clinical implementation of siRNA
therapy requires optimisation of delivery, dosage
and timing, however. Also, questions of allele-
specific silencing and side effects remain to be
addressed. Despite these potential obstacles,
RNA interference nonetheless remains a pro-
mising therapeutic strategy. If proven feasible,
siRNA therapies could be effective in a consi-
derable number of polyglutamine and other dis-
orders where preventing the accumulation of a
toxic gene product could avert or greatly diminish
pathogenesis.
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